Key result
Targeting the Kv1.3 potassium channel with its inhibitors shows potential beneficial effects in chronic kidney disease, suggesting it may serve as a novel therapeutic target.
Why the study?
Innovative therapeutic strategies to mitigate the progression of chronic kidney disease are needed due to the limitations of existing treatments.
Do Kv1.3 channel inhibitors mitigate the progression of chronic kidney disease?
Do Kv1.3 channel inhibitors mitigate the progression of chronic kidney disease?
Kv1.3 channel inhibitors show potential as a novel therapeutic strategy for the treatment of chronic kidney disease.
Hypothesis-generating for Kv1.3 inhibition in CKD; prospective trials needed before clinical consideration.
Chronic kidney disease (CKD), a global public health problem, causes substantial morbidity and mortality worldwide. Innovative therapeutic strategies to mitigate the progression of CKD are needed due to the limitations of existing treatments. Kv1.3, a voltage-gated potassium ion channel, plays a crucial role in multiple biological processes, including cell proliferation, apoptosis, energy homeostasis, and migration. Inhibition of the Kv1.3 channels has shown beneficial effects in the therapy of a wide range of human diseases such as cancer, autoimmune and neuroinflammatory diseases. Increasing evidence reveals a close link between Kv1.3 and CKD. This review summarises the most recent insights into the physiological functions of the Kv1.3 channel and its pharmacological modulators. Furthermore, the therapeutic potential of targeting Kv1.3 for CKD is also discussed. Collectively, these studies suggested that Kv1.3 channels may serve as a novel target for CKD therapy. • Kv1.3 channels play a pivotal role in cell proliferation, apoptosis, energy homeostasis and migration. • Due to its multiple biophysical and pharmacological properties, numerous inhibitors of Kv1.3 have been developed. • Targeting Kv1.3 with its inhibitors has shown potential beneficial effects in CKD. • Further studies are needed to apply the channel inhibitors as therapeutic agents for the treatment of CKD.
No takes yet. Share an insight, caveat, or question.
Dragan et al. (2024) conducted a review in Chronic kidney disease (CKD). Kv1.3 channel inhibitors was evaluated. Targeting the Kv1.3 potassium channel with its inhibitors shows potential beneficial effects in chronic kidney disease, suggesting it may serve as a novel therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: